Compare ELUT & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | TENX |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.8M | 56.2M |
| IPO Year | 2020 | 2001 |
| Metric | ELUT | TENX |
|---|---|---|
| Price | $1.07 | $10.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $22.50 |
| AVG Volume (30 Days) | 172.6K | ★ 181.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.14 | ★ 96.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,375,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $4.64 |
| 52 Week High | $3.46 | $18.38 |
| Indicator | ELUT | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 36.33 |
| Support Level | $0.86 | $5.99 |
| Resistance Level | $1.15 | $14.15 |
| Average True Range (ATR) | 0.14 | 0.83 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 13.24 | 2.33 |
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.